CONMED (CNMD) Stock Forecast & Price Target

Conmed Corp has demonstrated impressive growth in its BioBrace product line, with a full release of the FDA-approved rotator cuff repair device expected in the third quarter of 2025, indicating strong future revenue potential. Additionally, the Foot & Ankle segment achieved double-digit growth despite facing supply constraints, signaling a positive outlook as these issues appear to be easing. The management's conservative revenue guidance emphasizes a commitment to a gradual revenue growth improvement in the second half of the year, supported by robust performance in high-growth areas such as AirSeal and Foot & Ankle.

Conmed Corp has experienced a notable decline in its stock price, with shares down approximately 27% year-to-date, signaling ongoing challenges in the company's turnaround efforts. The downward adjustment of their price target from $80 to $68 reflects concerns over the company's performance, particularly in international markets, which are struggling against difficult year-over-year comparisons. Additionally, the capital weakness observed in the latest quarter cannot solely be attributed to a general slowdown in hospital capital budgets, which indicates potential underlying issues that may impact future growth prospects.